Updated Terms of UseNew Privacy PolicyYour Privacy ChoicesClosed Caption PolicyHelpContact UsAccessibility Statement This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal
Navigating Endocrine Resistance: Latest Strategies in HR+/HER2- Breast Cancer CareWhile endocrine therapies are widely employed for treating HR+/HER2- breast cancer, many patients with advanced or metastatic disease eventually develop resistance. As the treatment landscape continues to evolve, it is important to stay up to date on key advancements in managing endocrine resistance in this setting.
リリース、障害情報などのサービスのお知らせ
最新の人気エントリーの配信
処理を実行中です
j次のブックマーク
k前のブックマーク
lあとで読む
eコメント一覧を開く
oページを開く